Plain-English translation of NCT07160179 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of medicine delivered as an injection into the eye, to see if it is safe and whether it can help slow or stop vision loss in people with geographic atrophy. Geographic atrophy is an advanced stage of age-related macular degeneration—a condition where cells in the back of the eye gradually break down, causing blurry or lost vision. This study will help doctors understand how the medication moves through your body and whether it works to protect your remaining vision.
Geographic atrophy is a serious condition that currently has very limited treatment options, and doctors need new approaches to help people preserve their eyesight. This trial is exploring whether this new medication can offer patients a better way to manage this condition.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication into your eye during visits to a clinic or hospital. The study has two stages: Stage 1 tests different doses given either once or twice, while Stage 2 compares the new medication to an existing approved treatment over about 22 months, followed by 3 months of follow-up visits. You will attend regular weekly visits for medical check-ups, blood tests, eye exams, and questionnaires to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
United States